FDA Determines Regulatory Review Period for FARXIGA Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially announced the regulatory review period for the patent extension of FARXIGA, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO).